The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with imp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Adv Ther
Main Authors: Malkin, Samuel J. P., Russel-Szymczyk, Monika, Psota, Marek, Hlavinkova, Lucia, Hunt, Barnaby
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2019
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822857/
https://ncbi.nlm.nih.gov/pubmed/31168765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00965-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki